Antibody Discovery Market Expected to Reach $17.2 Billion by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “Antibody Discovery Market," The antibody discovery market size was valued at $6.9 billion in 2022, and is estimated to reach $17.2 billion by 2032, growing at a CAGR of 9.6% from 2023 to 2032. Antibody discovery is the process of identifying and characterizing antibodies that aim to recognize and bind to a specific antigen. The process of antibody discovery is divided into two major steps, such as lead antibody identification and lead optimization. The antibody is discovered for wide range of applications such as diagnostics, therapeutics, and research activities. In diagnostics, antibody is used to detect the presence of a specific antigen in a sample. In therapeutics, antibody is used to target and destroy specific antigen, for treatment of autoimmune diseases, hereditary diseases, cancer, and human immunodeficiency disease (HIV).

The major factors that drive the growth of global antibody discovery market size include increase in prevalence of disease such as asthma, rheumatoid arthritis, cancer, infectious disease and surge in need for better diagnostics & therapies. In addition, growth in number of investment for development of novel vaccine & therapeutics and increase in demand for antibody in various biotechnology & research industry propel the growth of the market. The monoclonal antibody therapy is used for the prevention and treatment of wide range of diseases such as various types of cancer, metabolic diseases, and auto immune diseases. In addition, some monoclonal antibodies are under regulatory review and undergo clinical trials to assess their potential for the treatment of viral infection. Moreover, in October 2022, Vir Biotechnology Inc., a biotechnology company, announced an investment of around $55 million from Biomedical Advanced R&D Authority for the development of VIR-2482. It is an investigational prophylactic monoclonal antibody, which is used in seasonal and pandemic influenza viruses infection.

In addition, increase in number of services by major antibody discovery industry, surge in demand for technologically advanced genetic platforms, rise in patient awareness toward applications of monoclonal antibodies (mAb) therapy, and upsurge in demand for high quality therapeutics antibody drive the market growth during the forecast period. The advanced technology and methods allow researchers to quickly generate and screen large libraries of antibodies to identify specific antibodies that can recognize and bind to a target antigen.  For instance, in March 2023, Twist Bioscience Corporation, one of the leading and rapidly growing synthetic biologic company, announced an integrated offering of antibody discovery services, which is available to customers. This includes the combination of Twist Biopharma synthetic library and artificial intelligent (AI) machine learning with an in vivo immunization approach, which is obtained through the acquisition of Abveris, a biotechnology company.

In addition, antibody discovery market trends include rise in demand for personalized medicine and increase in launch of antibody discovery platform. For instance, in October 2022, Bio Rad, one of the global leader in life science research and clinical diagnostic product, announced the launch of pioneer antibody discovery platform for therapeutic development. Moreover, in February 2021, RxCelerate, one of the leading international out-source drug discovery and development platform, announced the launch of Galaxy, which is a next generation antibody discovery platform.

However, the high cost of antibody discovery process negatively impacts the growth of the market. On the contrary,  the presence of pharmaceutical & biotechnology industries and increase in demand for therapeutic antibodies products provides an opportunity for the growth of the antibody discovery market.

On the basis of method, the antibody discovery market share is classified into phage display, hybridoma, and others. The others include single cell based method and transgenic mouse method. The phage display segment was the largest revenue contributor to the market in 2022, due to advantage of phage display method over other antibody discovery method.

On the basis of antibody type, the market is divided into humanized antibody, human antibody, chimeric antibody, and murine antibody. The humanized antibody segment was the highest revenue contributor to the market in 2022 and is expected to be the fastest growing segment during the antibody discovery market forecast due to rise in acceptance and adoption of human antibody drug. Human antibodies are more specific, stable, and cost-effective than murine, chimeric, and humanized antibodies.

On the basis of end user, the market is categorized into pharmaceutical & biotechnology industry, research laboratory, and academic laboratory. The pharmaceutical and biotechnology industry segment dominated the market in 2022 and is expected to continue this trend during the forecast period owing to rise in R&D activities in pharmaceutical & biotechnology industry and surge in expenditure by government to develop advanced pharmaceutical and biotechnology sector.

Region wise, North America had the highest antibody discovery market share in 2022, and is expected to maintain its lead during the forecast period, owing to increase in number of chronic diseases, rise in demand for antibody, surge in R&D activities in pharmaceutical sector, and strong presence of antibody discovery industry in this region. However, Asia-Pacific is expected to exhibit fastest growth during the forecast period owing to high prevalence of aging population with increased need of personalized antibody, increase in government fund for development of antibody therapeutics, and surge in healthcare expenditure.

The COVID-19 pandemic has highlighted the importance of antibody discovery and has led to significant advances in this field. For instance, Genscript, works on COVID-19 antibody discovery using single B cell screening technology. Moreover, Creative biolab, also works on COVID-19 antibody discovery from premade phage displayed human antibody library. Thus, the COVID-19 outbreak is anticipated to have a positive impact on the growth of the global antibody discovery market analysis.

Key Findings of The Study

• By method, phage display segment dominated the market in 2022.
• By antibody type, human antibody segment dominated the market in 2022.
• By end user, pharmaceutical and biotechnology industry segment dominated the market in 2022.
• By region, North America dominated the market in 2022. However, Asia-Pacific is expected to register highest CAGR during the forecast period.